About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

A Phase 1, Open Label, Randomized, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Weak Inducer Rufinamide on the Pharmacokinetics of Quizartinib in Healthy Subjects

NCT06740825•Daiichi Sankyo

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Healthy Subjects

Interventions

Quizartinib

Rufinamide

Locations

1

United States

Locations (1)

WCT

San Antonio, Texas, United States

Key Dates

Start Date

October 29, 2024

Primary Completion Date

December 9, 2024

Completion Date

December 9, 2024

Last Updated

December 18, 2024

Related Studies

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

RECRUITINGEARLY Phase 1

Single-tracer Multiparametric PET Imaging

NCT06014515

Healthy SubjectsCardiovascular Disease

RECRUITINGPhase 1

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT07219940

Healthy SubjectsExosome+1 more

Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities

NCT07059858

Intellectual DisabilityHealthy Subjects

RECRUITINGPhase 1

PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers

NCT07144176

Healthy Subjects

Physiological and Mood Changes After Walking in Green Spaces. A Comparison of Environments.

NCT07114146

Healthy Subjects (HS)Forest Therapy+2 more

View all related studies

Sponsors

Lead Sponsor

Daiichi Sankyo

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions